Literature DB >> 19664735

Direct healthcare costs of hip, vertebral, and non-hip, non-vertebral fractures.

Nianwen Shi1, Kathleen Foley, Gregory Lenhart, Enkhe Badamgarav.   

Abstract

Limited data exist regarding the cost of non-hip, non-vertebral (NHNV) fractures. Although NHNV fractures may be less expensive than hip and vertebral fractures, they have a higher incidence rate. The objective of this study was to quantify first-year healthcare costs of hip, vertebral, and NHNV fractures. This was a claims-based retrospective analysis using a case-control design among patients with commercial insurance and Medicare employer-based supplemental coverage. Patients were > or =50 years old with a closed hip, vertebral, or NHNV fracture between 7/1/2001 and 12/31/2004, and continuous enrollment 6 months prior to and 12 months after the index fracture. Adjusted mean first-year healthcare costs associated with these fractures were determined. Six cohorts were identified. Patients 50-64 years: NHNV (n=27,424), vertebral (n=3386) and hip (n=2423); patients > or =65 years: NHNV (n=40,960), vertebral (n=11,751) and hip (n=21,504). The ratio of NHNV to hip fractures was 11:1 in the 50-64 cohort and 2:1 in the > or =65 cohort. Adjusted mean first-year costs associated with hip, vertebral, and NHNV fractures were $26,545, $14,977, and $9183 for the 50-64 age cohort, and $15,196, $6701, and $6106 for patients > or =65 years. After taking prevalence rate into account, the proportion of the total fracture costs accounted for by NHNV, hip, and vertebral fractures were 66%, 21% and 13% for the 50-64 age cohort, and 36%, 52% and 12% for the > or =65 age cohort. Limitations included the exclusion of the uninsured and those covered by Medicaid or military-based insurance programs. The results of this study demonstrate that osteoporotic fractures are associated with significant costs. Although NHNV fractures have a lower per-patient cost than hip or vertebral fractures, their total first-year cost is greater for those 50-64 because of their higher prevalence.

Entities:  

Mesh:

Year:  2009        PMID: 19664735     DOI: 10.1016/j.bone.2009.07.086

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  27 in total

1.  Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate.

Authors:  D L Kendler; M R McClung; N Freemantle; M Lillestol; A H Moffett; J Borenstein; S Satram-Hoang; Y-C Yang; P Kaur; D Macarios; S Siddhanti
Journal:  Osteoporos Int       Date:  2010-09-09       Impact factor: 4.507

2.  Neurologist care in Parkinson disease: a utilization, outcomes, and survival study.

Authors:  A W Willis; M Schootman; B A Evanoff; J S Perlmutter; B A Racette
Journal:  Neurology       Date:  2011-08-10       Impact factor: 9.910

3.  Hip fracture incidence is decreasing in the high incidence area of Oslo, Norway.

Authors:  R O Støen; L Nordsletten; H E Meyer; J F Frihagen; J A Falch; C M Lofthus
Journal:  Osteoporos Int       Date:  2012-01-14       Impact factor: 4.507

Review 4.  The definition and clinical significance of nonvertebral fractures.

Authors:  Jacqueline R Center
Journal:  Curr Osteoporos Rep       Date:  2010-12       Impact factor: 5.096

Review 5.  Osteoporotic fractures: a systematic review of U.S. healthcare costs and resource utilization.

Authors:  Sangeeta Budhia; Yeshi Mikyas; Michael Tang; Enkhe Badamgarav
Journal:  Pharmacoeconomics       Date:  2012-02-01       Impact factor: 4.981

6.  Direct medical costs attributable to peripheral fractures in Canadian post-menopausal women.

Authors:  L Bessette; S Jean; M-P Lapointe-Garant; E L Belzile; K S Davison; L G Ste-Marie; J P Brown
Journal:  Osteoporos Int       Date:  2011-09-17       Impact factor: 4.507

Review 7.  Temporal trends in the incidence of osteoporotic fractures.

Authors:  S N Morin; L M Lix; S R Majumdar; W D Leslie
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

8.  Severe osteoporosis: diagnosis of non-hip non-vertebral (NHNV) fractures.

Authors:  Giovanni D'Elia; Giuliana Roselli; Loredana Cavalli; Paolo Innocenti; Maria Luisa Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2010-05

9.  Direct healthcare costs for 5 years post-fracture in Canada: a long-term population-based assessment.

Authors:  W D Leslie; L M Lix; G S Finlayson; C J Metge; S N Morin; S R Majumdar
Journal:  Osteoporos Int       Date:  2013-01-23       Impact factor: 4.507

10.  Aromatase inhibitors associated musculoskeletal disorders and bone fractures in postmenopausal breast cancer patients: a result from Chinese population.

Authors:  Lu Xu; Jue Wang; Dan-Dan Xue; Wei He
Journal:  Med Oncol       Date:  2014-07-24       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.